Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ipsen receives EU approval for renal cell carcinoma therapy Cabometyx

Ipsen receives EU approval for renal cell carcinoma therapy Cabometyx

28th September 2016

Ipsen has announced that its new advanced renal cell carcinoma therapy Cabometyx has been approved by the European Commission.

The tablet-based therapy has been ratified for the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor-targeted therapy. It offers a unique mechanism of action, with the potential to overcome resistance to existing therapies.

Cabometyx is the only single agent to demonstrate significant clinical benefits in terms of overall survival, objective response rate and progression-free survival in a phase III study conducted among previously-treated patients with renal cell carcinoma.

As it has been proven to prolong survival, slow disease progression and shrink tumours with a clinically acceptable safety and tolerability profile, it is hoped that the drug can become a new standard of care for second-line treatment of this disease.

David Meek, chief executive officer of Ipsen, said: "The approval of Cabometyx in Europe provides a breakthrough treatment to physicians and their patients suffering from renal cancer who failed on initial therapy."

The drug was approved by the US Food and Drug Administration in April for the treatment of patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy. 

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801825882-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.